BioSpace News Archive

Acceleron Pharma Inc. announced it will host a conference call and webcast on Wednesday, June 24, 2020 at 4:30 p.m. EDT to review the topline results of the PULSAR Phase 2 trial of sotatercept in patients with pulmonary arterial hypertension.

Poster presentation of pharmacodynamic and safety data of cavrotolimod (AST-008) from Exicure’s ongoing Phase 1b/2 clinical trial in solid tumor patients

Chinese biologic drug developer SinocellTech, Qiming’s portfolio company, lands on the Science and Technology Innovation Board.

MAX32670 saves 40 percent power and 50 percent space, includes ECC-protected memory for increased equipment uptime

Start Codon aims to rapidly translate the most disruptive and innovative life science research into successful companies and positive clinical outcomes

SpringWorks Therapeutics, Inc. announced that the first patient has been dosed in a Phase 1b clinical trial evaluating SpringWorks Therapeutics’ investigational gamma secretase inhibitor, nirogacestat, in combination with GlaxoSmithKline’s investigational anti-B-cell maturation antigen antibody-drug conjugate, belantamab mafodotin, in patients with relapsed or refractory multiple myeloma.

Upgraded Manufacturing Process Being Used For Production Of Pivotal Stage Clinical Trial Materials

FibroGen, Inc. announced the appointment of Thane Wettig to the newly-created position of Chief Commercial Officer, where he will lead FibroGen’s commercialization efforts, leveraging more than 30 years of global biopharmaceutical leadership and experience.

Oral Science International, announces the Canadian launch of COLD & FLU GUARD™ for Health Care Professionals and for all those worried about the damaging effects of viruses on their work, daily lives, and society.

Agenus Inc. announced that it has entered into an agreement with Betta Pharmaceuticals, a top Chinese pharmaceutical company focusing on the development of innovative oncology therapies, for an exclusive collaboration and license agreement for the development and commercialization of balstilimab and zalifrelimab in Greater China, including Mainland China, Hong Kong, Macau and Taiwan.